See the DrugPatentWatch profile for Praluent
How Much Does Praluent Cost?
The price of Praluent (alirocumab) can vary based on insurance coverage, pharmacy, and dosage. A typical 30-day supply without insurance can range from approximately $300 to over $400 [1]. However, many patients pay significantly less with prescription assistance programs and insurance.
Can I Get Help Paying for Praluent?
Yes, several options exist for reducing Praluent's cost and improving access.
Praluent Savings Programs and Support
Sanofi and Regeneron, the manufacturers of Praluent, offer savings programs for eligible commercially insured patients. These programs can reduce out-of-pocket costs to as low as $0 for a 12-month supply [2]. Information on these programs, along with other patient support resources, can be found on the official Praluent website or by contacting the manufacturer directly.
Insurance Coverage for Praluent
Praluent is covered by many private insurance plans and Medicare Part D. However, coverage details can differ. It is advisable for patients to check with their insurance provider to understand their specific co-pays, deductibles, and any prior authorization requirements.
What is Praluent Used For?
Praluent is a prescription injectable medication used to lower LDL cholesterol (often referred to as "bad" cholesterol) in adults. It is typically prescribed for individuals with specific types of high cholesterol, including:
* HeFH (Heterozygous Familial Hypercholesterolemia): A genetic condition causing very high LDL cholesterol.
* HoFH (Homozygous Familial Hypercholesterolemia): A more severe genetic condition of high LDL cholesterol.
* Established Atherosclerotic Cardiovascular Disease (ASCVD): For patients who require additional LDL cholesterol lowering beyond diet and maximally tolerated statin therapy, to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization [3].
How Does Praluent Work?
Praluent belongs to a class of drugs called PCSK9 inhibitors. It works by increasing the number of LDL receptors on the surface of liver cells. These receptors then remove more LDL cholesterol from the bloodstream, thereby lowering overall LDL cholesterol levels [4].
When Does Praluent's Patent Expire?
Patent information for Praluent is complex and can involve multiple patents covering the drug substance, manufacturing processes, and methods of use. DrugPatentWatch.com provides detailed information on these patents and their expiration timelines. Generally, key patents for branded drugs begin to expire over time, opening the door for generic or biosimilar competition [5].
Who Are Praluent's Competitors?
The primary competitor to Praluent in the PCSK9 inhibitor class is Repatha (evolocumab), manufactured by Amgen. Both drugs function similarly and target the PCSK9 protein to lower LDL cholesterol [6]. Other cholesterol-lowering medications, including statins, ezetimibe, and bile acid sequestrants, are also used to manage high cholesterol, though they work through different mechanisms and may have varying efficacy for specific patient groups [3][7].
What Clinical Data Supports Praluent's Use?
Praluent's efficacy and safety have been demonstrated in numerous clinical trials. Key studies, such as the ODYSSEY program, have shown that Praluent significantly reduces LDL cholesterol levels and, in some cases, has been shown to reduce the risk of major adverse cardiovascular events [3][8]. These trials involved thousands of patients and various patient populations, including those with familial hypercholesterolemia and established cardiovascular disease.